Dexamethasone and interleukin‐2 combination therapy for advanced renal cell carcinoma in a patient with paraneoplastic inflammatory syndrome

Interleukin‐2 (IL‐2) in combination with dexamethasone was administered to a 48‐year‐old man with renal cell carcinoma accompanied by paraneoplastic inflammatory syndrome, including progressive multiple lung metastases and inferior vena caval tumor thrombus. Although non‐steroidal anti‐inflammatory...

Full description

Saved in:
Bibliographic Details
Published in:International journal of urology 2004-07, Vol.11 (7), p.553-556
Main Authors: SHINOJIMA, TOSHIAKI, OYA, MOTOTSUGU, KOHNO, HIDAKA, MARUMO, KEN, MURAI, MASARU
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Renal Cell - complications
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - pathology
dexamethasone
Dexamethasone - administration & dosage
Disease Progression
Humans
immunotherapy
Inflammation - drug therapy
Inflammation - etiology
Interleukin-2 - administration & dosage
Kidney Neoplasms - complications
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Male
Middle Aged
Paraneoplastic Syndromes - drug therapy
Paraneoplastic Syndromes - etiology
renal cell carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interleukin‐2 (IL‐2) in combination with dexamethasone was administered to a 48‐year‐old man with renal cell carcinoma accompanied by paraneoplastic inflammatory syndrome, including progressive multiple lung metastases and inferior vena caval tumor thrombus. Although non‐steroidal anti‐inflammatory drugs had no apparent antipyretic effect on the systemic inflammatory syndrome, oral administration of dexamethasone achieved complete antipyresis and improved his quality of life. After a 4‐week period of IL‐2 treatment, regression of metastasized lesions was demonstrated despite concurrent oral administration of dexamethasone. Steroids might reduce the action of immunotherapeutic drugs, but in some cases, combination therapy can achieve both alleviation of the paraneoplastic syndrome and tumor shrinkage.
ISSN:0919-8172
1442-2042
DOI:10.1111/j.1442-2042.2004.00831.x